Issue: April 2011
April 01, 2011
1 min read
Save

Chewable integrase inhibitor tablets helped control HIV-1 in pediatric patients

Issue: April 2011
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Chewable tablets containing the integrase inhibitor raltegravir appeared to help pediatric patients aged 2 to 5 years control HIV-1, according to a poster presentation.

Sharon Nachman, MD, professor of pediatrics at Stony Brook University Medical Center in New York, and colleagues enrolled 12 HIV-1 patients, aged 2 to 5 years, in a dose-finding study with intensive pharmacokinetic and safety and virologic response. Only children with HIV RNA of more than 1,000 copies/mL and prior exposure to antiretroviral therapy, but no exposure to integrase inhibitors, were included. The median age for participants was 3 years; 67% were girls, 75% were black, and all were within 1 year of 3 years of age.

Besides their existing ART regimen, participants were given a twice-daily weight-based dosing (6 mg/kg, 300-mg dose maximum) of raltegravir (Isentress, Merck Sharp & Dohme) in a chewable tablet. The blood levels of raltegravir were tested after the children had been on raltegravir for at least 5 days. Results were compared with existing data from 6- to 18-year-old HIV patients (n=10) who received the adult formulation, and to 6- to 11-year-old HIV patients (n=10) given the chewable raltegravir tablet.

Dr. Sharon Nachman
Dr. Sharon Nachman

By week 12, researchers noted virologic success in 75% (95% CI, 43-95) of patients; and by week 24, 60% (95% CI, 26-88) of participants showed virologic success.

Nachman and colleagues said administering chewable tablets of raltegravir to 2- to 5-year-olds with HIV-1 appeared to be generally safe and well tolerated.

For more information:

  • Nachman S. Abstract #715.

Disclosure: Dr. Nachman reports no relevant financial disclosures.